Public Health Implications of Household Pharmaceutical Waste in the United States

Health Services Insights

Volumn 3, Issue , 2010, Pages

  Bain, Kevin T ^a  

^a excelleRx Inc   (United States)

Author keywords

environmental pollutants; pharmaceutical preparations; pharmaceutical waste; public health; waste management; water pollutants

Indexed keywords

EID: 84896723728     PISSN: None     EISSN: 11786329     Source Type: Journal    
DOI: 10.4137/HSI.S4673     Document Type: Review

References (87)

1. The Associated Press. Tons of drugs dumped into wastewater. Available at: http://www.msnbc.msn.com/id/26706059/print/1/displaymode/1098/. Accessed Nov 4, 2008.
2. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/Prescription-Drug-Trends-October-2004-UPDATE.pdf. Accessed Oct 13, 2008.
3. Catlin A., Cowan C., Hartman M., Heffler S., National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008; 27: 14–29.
4. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.amsa.org/business/Kaiser%20Foundation%20drug%20trends.pdf. Accessed Jan 11, 2009.
5. Block G., Cox C., Madans J., Schreiber G.B., Licitra L., Melia N., Vitamin supplement use, by demographic characteristics. Am J Epidemiol. 1988; 127: 297–309.
6. Ervin R.B., Wright J.D., Kennedy-Stephenson J., Use of dietary supplements in the United States, 1988–94. Vital Health Stat 11. 1999(244): i–iii, 1–14.
7. Hanlon J.T., Fillenbaum G.G., Ruby C.M., Gray S., Bohannon A., Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging. 2001; 18: 123–31.
8. Koplan J.P., Annest J.L., Layde P.M., Rubin G.L., Nutrient intake and supplementation in the United States (NHANES II). Am J Public Health. 1986; 76: 287–9.
9. Radimer K., Bindewald B., Hughes J., Ervin B., Swanson C., Picciano M.F., Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000. Am J Epidemiol. 2004; 160: 339–49.
10. Qato D.M., Alexander G.C., Conti R.M., Johnson M., Schumm P., Lindau S.T., Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008; 300: 2867–78.
11. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., Mitchell A.A., Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287: 337–44.
12. American Society of Consultant Pharmacists. Reducing Pharmaceutical Waste. Alexandria, VA: American Society of Consultant Pharmacists; 2009.
13. Paone R.P., Vogenberg F.R., Caporello E., Rutkowski J., Parent R., Fachetti F., Medication destruction and waste measurement and management in long-term care facilities. Consult Pharm. 1996; 11: 32–40.
14. Garey K.W., Johle M.L., Behrman K., Neuhauser M.M., Economic consequences of unused medications in Houston, Texas. Ann Pharmacother. 2004; 38: 1165–8.
15. Cameron S., Study by Alberta pharmacists indicates drug wastage a “mammoth” problem. CMAJ. 1996; 155: 1596–8.
16. Macarthur D., Any old drugs? Two schemes for the disposal of unwanted medicines in Europe. Pharmaceut J. 2000; 264: 223–4.
17. National Hospice and Palliative Care Organization. NHPCO Facts and Figures: Hospice Care in America. Alexandria, VA: National Hospice and Palliative Care Organization, Office of Research; 2009.
18. Koh N.Y., Koo W.H., Polypharmacy in palliative care: can it be reduced? Singapore Med J. 2002; 43: 279–83.
19. Zeppetella G., How do terminally ill patients at home take their medication? Palliat Med. 1999; 13: 469–75.
20. Maxwell T., Jackson-Woods C., Steward K., Knowlton M., Liao D., Controlled substance waste in home hospice settings [abstract]. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May/Jun, 2008; Toronto, ON, Canada.
21. Hauser J.M., Chen L., Paice J., Down the drain: the cost of medications wasted in hospice. J Pain Symptom Manage. 2006; 31: 379–80.
22. Ruhoy I.S., Daughton C.G., Types and quantities of leftover drugs entering the environment via disposal to sewage—revealed by coroner records. Sci Total Environ. 2007; 388: 137–48.
23. Kreisberg J., Greener pharmacy: proper medicine disposal protects the environment. Integrat Med. 2007; 6: 50–2.
24. Office of National Drug Control Policy. Proper disposal of prescription drugs. Feb 2007. Available at: http://www.whitehousedrugpolicy.gov/publications/pdf/prescrip_disposal.pdf. Accessed Oct 13, 2008.
25. Office of National Drug Control Policy. Proper disposal of prescription drugs. Oct 2009. Available at: http://www.whitehousedrugpolicy.gov/publications/pdf/prescrip_disposal.pdf. Accessed Oct 21, 2009.
26. U.S. Food and Drug Administration. Disposal by flushing of certain unused medicines: what you should know. Available at: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm. Accessed Oct 21, 2009.
27. Becker J., Minding the Gap: Research Priorities to Address Pharmaceuticals in the Environment. Chicago, IL: University of Illinois at Chicago School of Public Health; 2010.
28. U.S. Environmental Protection Agency. Unused Pharmaceuticals in the Health Care Industry: Interim Report. Washington, DC: U.S. Environmental Protection Agency; 2008.
29. U.S. Environmental Protection Agency. Amendment to the Universal Waste Rule: Addition of Pharmaceuticals. Washington, DC: U.S. Environmental Protection Agency; 2008.
30. American Pharmacists Association. Environmental Protection Agency Proposed Rule: Amendment to the Universal Waste Rule: Addition of Pharmaceuticals. Washington, DC: American Pharmacists Association; 2009.
31. American Pharmacists Association. Drug Enforcement Agency: Advance Notice of Proposed Rulemaking and Request for Comment: Disposal of Controlled Substances by Persons not Registered with Drug Enforcement Administration. Washington, DC: American Pharmacists Association; 2009.
32. U.S. Drug Enforcement Administration. Disposal of Controlled Substances by Persons Not Registered With the Drug Enforcement Administration. Springfield, VA: U.S. Department of Justice; 2009.
33. Centers for Medicare and Medicaid Services. Medicare and Medicaid Programs: Hospice Conditions of Participation. Baltimore, MD: U.S. Department of Health and Human Services; 2008.
34. Halling-Sørensen B., Nielsen S.N., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E., Occurrence, fate and effects of pharmaceutical substances in the environment—a review. Chemosphere. 1998; 36: 357–93.
35. 14C-sarafloxacin hydrochloride in soil. Environmental Toxicology and Chemistry. 1997; 16: 462–71.
36. Weerasinghe C.A., Towner D., Aerobic biodegradation of virginiamycin in soil. Environmental Toxicology and Chemistry. 1997; 16: 1873–6.
37. Kummerer K., Significance of antibiotics in the environment. J Antimicrob Chemother. 2003; 52: 5–7.
38. Figueroa R.A., MacKay A.A., Sorption of oxytetracycline to iron oxides and iron oxide-rich soils. Environ Sci Technol. 2005; 39: 6664–71.
39. Chang P.H., Li Z., Jiang W.T., Jean J.S., Adsorption and intercalation of tetracycline by swelling clay minerals. Applied Clay Science. 2009; 46: 27–36.
40. Chang P.H., Jean J.S., Jiang W.T., Li Z., Mechanism of tetracycline sorption on rectorite. Colloids and Surfaces A: Physicochem Eng Aspects. 2009; 339: 94–9.
41. Li Z., Chang P.H., Jean J.S., Jiang W.T., Wang C.J., Interaction between tetracycline and smectite in aqueous solution. J Colloid Interface Sci. 2010; 341: 311–9.
42. Hospitals for a Healthy Environment. Pharmaceutical waste minimization. Available at: http://cms.h2e-online.org/ee/waste-reduction/waste-minimization/pharma/. Accessed Feb 26, 2009.
43. Kolpin D.W., Furlong E.T., Meyer M.T., et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: a national reconnaissance. Environ Sci Technol. 2002; 36: 1202–11.
44. Hirsch R., Ternes T., Haberer K., Kratz K.L., Occurrence of antibiotics in the aquatic environment. Sci Total Environ. 1999; 225: 109–18.
45. Holm J.V., Rugge K., Bjerg P.L., Christensen T.H., Occurrence and distribution of pharmaceutical organic compounds in the groundwater downgradient of a landfill (Grindsted, Denmark). Environ Sci Technol. 1995; 29: 1415–20.
46. Stumpf M., Ternes T.A., Wilken R.D., Rodrigues S.V., Baumann W., Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. Sci Total Environ. 1999; 225: 135–41.
47. Ternes T.A., Occurrence of drugs in German sewage treatment plants and rivers. Water Research. 1998; 32: 3245–60.
48. The Associated Press. Pharmaceuticals lurking in U.S. drinking water. Available at: http://www.msnbc.msn.com/id/23503485//. Accessed Nov 4, 2008.
49. Daughton C.G., Ternes T.A., Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect. 1999; 107 Suppl 6: 907–38.
50. Baronti C., Curini R., D'Ascenzo G., Di Corcia A., Gentili A., Samperi R., Monitoring natural and synthetic estrogens at activated sludge sewage treatment plants and in a receiving river water. Environ Sci Technol. 2000; 34: 5059–66.
51. Liney K.E., Jobling S., Shears J.A., Simpson P., Tyler C.R., Assessing the sensitivity of different life stages for sexual disruption in roach (Rutilus rutilus) exposed to effluents from wastewater treatment works. Environ Health Perspect. 2005; 113: 1299–307.
52. Nash J.P., Kime D.E., van der Ven L.T., et al. Long-term exposure to environmental concentrations of the pharmaceutical ethynylestradiol causes reproductive failure in fish. Environ Health Perspect. 2004; 112: 1725–33.
53. Routledge E.J., Sheahan D., Desbrow C., Brighty G.C., Waldock M., Sumpter J.P., Identification of estrogenic chemicals in STW effluent. 2. In vivo responses in trout and roach. Environ Sci Technol. 1998; 32: 1559–65.
54. Blazer V.S., Iwanowicz L.R., Iwanowicz D.D., et al. Intersex (testicular oocytes) in smallmouth bass from the Potomac River and selected nearby drainages. J Aquat Anim Health. 2007; 19: 242–53.
55. Feist G.W., Webb M.A., Gundersen D.T., et al. Evidence of detrimental effects of environmental contaminants on growth and reproductive physiology of white sturgeon in impounded areas of the Columbia River. Environ Health Perspect. 2005; 113: 1675–82.
56. An W., Hu J., Effects of endocrine disrupting chemicals on China's rivers and coastal waters. Front Ecol Environ. 2006; 4: 378–86.
57. Jobling S., Beresford N., Nolan M., et al. Altered sexual maturation and gamete production in wild roach (Rutilus rutilus) living in rivers that receive treated sewage effluents. Biol Reprod. 2002; 66: 272–81.
58. Jobling S., Nolan M., Tyler C.R., Brighty G., Sumpter J.P., Widespread sexual disruption in wild fish. Environ Sci Technol. 1998; 32: 2498–506.
59. U.S. Geological Survey. Summary of U.S. Geological Survey (USGS) Information Related to the Intersex Characteristics of Fish in the Potomac Watershed. Reston, VA: U.S. Department of the Interior; 2006.
60. Wolff M.S., Britton J.A., Wilson V.P., Wolff M.S., Britton J.A., Wilson V.P., Environmental risk factors for breast cancer among African-American women. Cancer. 2003; 97 Suppl 1: 289–310.
61. Davis D.L., Bradlow H.L., Can environmental estrogens cause breast cancer? Sci Am. 1995; 273: 167–72.
62. Davis D.L., Bradlow H.L., Wolff M., Woodruff T., Hoel D.G., Anton-Culver H., Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect. 1993; 101: 372–7.
63. Walker A.H., Bernstein L., Warren D.W., Warner N.E., Zheng X., Henderson B.E., The effect of in utero ethinyl oestradiol exposure on the risk of cryptorchid testis and testicular teratoma in mice. Br J Cancer. 1990; 62: 599–602.
64. Yasuda Y., Kihara T., Tanimura T., Effect of ethinyl estradiol on the differentiation of mouse fetal testis. Teratology. 1985; 32: 113–8.
65. Yasuda Y., Kihara T., Tanimura T., Nishimura H., Gonadal dysgenesis induced by prenatal exposure to ethinyl estradiol in mice. Teratology. 1985; 32: 219–27.
66. Sharpe R.M., Skakkebaek N.E., Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet. 1993; 341: 1392–5.
67. Harrison P.T., Holmes P., Humfrey C.D., Reproductive health in humans and wildlife: are adverse trends associated with environmental chemical exposure? Sci Total Environ. 1997; 205: 97–106.
68. Ash R.J., Mauck B., Morgan M., Antibiotic resistance of gram-negative bacteria in rivers, United States. Emerg Infect Dis. 2002; 8: 713–6.
69. Mispagel H., Gray J.T., Antibiotic resistance from wastewater oxidation ponds. Water Environ Res. 2005; 77: 2996–3002.
70. Stepanauskas R., Glenn T.C., Jagoe C.H., et al. Coselection for microbial resistance to metals and antibiotics in freshwater microcosms. Environ Microbiol. 2006; 8: 1510–4.
71. Chee-Sanford J.C., Aminov R.I., Krapac I.J., Garrigues-Jeanjean N., Mackie R.I., Occurrence and diversity of tetracycline resistance genes in lagoons and groundwater underlying two swine production facilities. Appl Environ Microbiol. 2001; 67: 1494–502.
72. Gilliver M.A., Bennett M., Begon M., Hazel S.M., Hart C.A., Antibiotic resistance found in wild rodents. Nature. 1999; 401: 233–4.
73. Khachatourians G.G., Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. CMAJ. 1998; 159: 1129–36.
74. Smith K.E., Besser J.M., Hedberg C.W., et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. Investigation Team. N Engl J Med. 1999; 340: 1525–32.
75. Christensen F.M., Pharmaceuticals in the environment—a human risk? Regul Toxicol Pharmacol. 1998; 28: 212–21.
76. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., Wargo J.P., A human health risk assessment of pharmaceuticals in the aquatic environment. Human and Ecological Risk Assessment. 2002; 8: 657–80.
77. Schwab B.W., Hayes E.P., Fiori J.M., et al. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharmacol. 2005; 42: 296–312.
78. Webb S., Ternes T., Gibert M., Olejniczak K., Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett. 2003; 142: 157–67.
79. Buzby M.E., Pharmaceuticals in the environment: PhRMA PIE perspective. Available at: http://www.dtsc.ca.gov/AssessingRisk/PPCP/upload/04_Buzby.pdf. Accessed May 15, 2010.
80. Morgan T.M., The economic impact of wasted prescription medication in an outpatient population of older adults. J Fam Pract. 2001; 50: 779–81.
81. Medicare Payment Advisory Commission. Report to the Congress: Reforming the Delivery System. Washington, DC: Medicare Payment Advisory Commission; 2008.
82. U.S. Environmental Protection Agency. Green chemistry. Available at: http://www.epa.gov/gcc/. Accessed May 15, 2010.
83. Stranahan S.Q., Drugs in our drinking water. What do we do with unused medicines? Available at: http://bulletin.aarp.org/yourhealth/policy/articles/drugs_in_our_drinking_water_.html. Accessed Mar 1, 2009.
84. Lee H-B, Peart T.E., Sarafin K., Svoboda M.L., Acidic pharmaceuticals in sewage—methodology, stability test, occurrence, and removal from Ontario samples. Water Qual Res J Canada. 2003; 38: 667–82.
85. Tauxe-Wuersch A., De Alencastro L.F., Grandjean D., Tarradellas J., Occurrence of several acidic drugs in sewage treatment plants in Switzerland and risk assessment. Water Res. 2005; 39: 1761–72.
86. Kimura K., Hara H., Watanabe Y., Removal of pharmaceutical compounds by submerged membrane bioreactors (MBRs). Desalination. 2005; 178: 135–40.
87. Dean C., Drugs are in the water. Does it matter? Available at: http://www.nytimes.com/2007/04/03/science/earth/03water.html?_r=1&oref=slogin&ref=h. Accessed Sep 28, 2007.